Table 4.

Associations of FGF23 and genotype interactions with the composite end point (50% decline in eGFR, ESKD, or death) in HALT-PKD Study A and B

FGF23 × Genotype GroupsHR (95% CI)
UnadjustedAdjusted
PKD1 nontruncating, FGF23 tertile 11.37 (0.85 to 2.21)0.82 (0.43 to 1.54)
PKD1 nontruncating, FGF23 tertile 21.02 (0.70 to 1.50)0.90 (0.57 to 1.43)
PKD1 nontruncating, FGF23 tertile 30.74 (0.53 to 1.02)1.01 (0.71 to 1.42)
PKD2, FGF23 tertile 10.19 (0.06 to 0.58)0.16 (0.05 to 0.50)
PKD2, FGF23 tertile 20.25 (0.11 to 0.59)0.26 (0.11 to 0.62)
PKD2, FGF23 tertile 30.35 (0.19 to 0.64)0.46 (0.24 to 0.86)
NMD, FGF23 tertile 11.15 (0.48 to 2.76)0.87 (0.31 to 2.44)
NMD, FGF23 tertile 20.81 (0.41 to 1.59)0.75 (0.36 to 1.57)
NMD, FGF23 tertile 30.55 (0.29 to 1.02)0.64 (0.32 to 1.26)
  • The reference group is PKD1 truncating for the same tertile of FGF23 in any given comparison. FGF23 tertile 1 is at 38.5 pg/ml; FGF23 tertile 2 is at 53.0 pg/ml; FGF23 tertile 3 is at 73.7 pg/ml. Adjusted model is adjusted for age, sex, body mass index, systolic BP, randomization group, calcium, phosphorus, baseline eGFR, and urinary albumin excretion. FGF23, fibroblast growth factor 23; HALT-PKD, Halt Progression of Polycystic Kidney Disease; HR, hazard ratio; NMD, no mutation detected.